Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

Bone Marrow Transplantation volume 53, pages 521–534 (2018)Cite this article

Subjects

A Correction to this article was published on 19 September 2018

This article has been updated

Abstract

Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring’s HLA antigens, and the degree of mismatch. Here we summarize the evidence for the role of DSA in the development of primary graft failure in haploidentical transplantation and provide consensus recommendations from the European Society for Blood and Marrow Transplant Group on testing, monitoring, and treatment of patients with DSA receiving haploidentical hematopoietic progenitor cell transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 19 September 2018

    The original version of this Article contained a typographical error in the spelling of the author Marcelo Fernandez-Vina, which was incorrectly given as Marcelo Fernadez-Vina. This has now been corrected in the PDF and HTML versions of the Article.

References

  1. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, et al. Gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19+ lymphocytes. Blood. 2015;125:2349–58. https://doi.org/10.1182/blood-2014-09-599423.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta + T and B cells in children with nonmalignant disorders. Blood. 2014;124:822–6.. https://doi.org/10.1182/blood-2014-03-563817.

    Article  CAS  PubMed  Google Scholar 

  3. Ciurea SO, Zhang M-J, Bacigalupo A, Bashey A, Appelbaum FR, Antin JH, et al. Survival after T-cell replete haplo-identical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor transplant for acute myeloid leukemia. Blood. 2014;124:679.

    Article  Google Scholar 

  4. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–50. https://doi.org/10.1038/nm915.

    Article  CAS  PubMed  Google Scholar 

  5. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant.2008;14:641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bastien JP, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S, et al. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood. 2010;116:4859–69. https://doi.org/10.1182/blood-2010-03-273193.

    Article  CAS  PubMed  Google Scholar 

  7. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396–405. https://doi.org/10.1038/leu.2014.180.

    Article  CAS  PubMed  Google Scholar 

  8. Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017. https://doi.org/10.3324/haematol.2017.176107.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008;14:859–66.. https://doi.org/10.1016/j.bbmt.2008.05.005.

    Article  PubMed  PubMed Central  Google Scholar 

  10. O’Reilly RJ, Keever C, Kernan NA, Brochstein J, Collins N, Flomenberg N, et al. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc. 1987;19:55–60.

    PubMed  Google Scholar 

  11. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991;7:443–52.

    CAS  PubMed  Google Scholar 

  12. Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1169–75. https://doi.org/10.1016/j.bbmt.2010.11.020.

    Article  PubMed  Google Scholar 

  13. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88:1019–24. https://doi.org/10.1097/TP.0b013e3181b9d710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54. https://doi.org/10.1200/jco.2005.09.117.

    Article  PubMed  Google Scholar 

  15. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–81. https://doi.org/10.1182/blood-2008-02-140095.

    Article  CAS  PubMed  Google Scholar 

  16. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010;45:429–36. https://doi.org/10.1038/bmt.2009.189.

    Article  CAS  PubMed  Google Scholar 

  17. Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, et al. Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood. 2014;124:843–50. https://doi.org/10.1182/blood-2014-03-563130.

    Article  CAS  PubMed  Google Scholar 

  18. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–22. https://doi.org/10.1016/j.bbmt.2012.08.014.

    Article  CAS  PubMed  Google Scholar 

  19. Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, et al. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol. 2016;9:25. https://doi.org/10.1186/s13045-016-0248-3.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000;96:4096–102.

    CAS  PubMed  Google Scholar 

  21. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–77. https://doi.org/10.1056/nejm199811263392201.

    Article  CAS  PubMed  Google Scholar 

  22. Murphy WJ, Kumar V, Bennett M, Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med. 1987;166:1499–509.

    Article  CAS  Google Scholar 

  23. Bordignon C, Kernan NA, Keever CA, Benazzi E, Small TN, Brochstein J, et al. The role of residual host immunity in graft failures following T-cell-depleted marrow transplants for leukemia. Ann N Y Acad Sci. 1987;511:442–6.

    Article  CAS  Google Scholar 

  24. Anasetti C, Logan BR, Confer DL, Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013;368:288. https://doi.org/10.1056/NEJMc1214025.

    Article  PubMed  Google Scholar 

  25. van Besien K, Shore T, Cushing M, Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013;368:287–8. https://doi.org/10.1056/NEJMc1214025#SA1.

    Article  PubMed  Google Scholar 

  26. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96. https://doi.org/10.1056/NEJMoa1203517.

    Article  CAS  PubMed  Google Scholar 

  27. Slot S, Smits K, van de Donk NW, Witte BI, Raymakers R, Janssen JJ, et al. Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. Bone Marrow Transplant. 2015;50:1424–31. https://doi.org/10.1038/bmt.2015.172.

    Article  CAS  PubMed  Google Scholar 

  28. Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant. 2015;50:S37–9. https://doi.org/10.1038/bmt.2015.93.

    Article  CAS  PubMed  Google Scholar 

  29. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21:1299–307. https://doi.org/10.1016/j.bbmt.2015.03.003.

    Article  PubMed  Google Scholar 

  30. Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102:1066–74. https://doi.org/10.3324/haematol.2016.160804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Warren RP, Storb R, Weiden PL, Su PJ, Thomas ED, Lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity in patients with aplastic anemia: distinguishing transfusion-induced sensitization from possible immune-mediated aplastic anemia. Transplant Proc. 1981;13:245–7.

    CAS  PubMed  Google Scholar 

  32. Xu H, Chilton PM, Tanner MK, Huang Y, Schanie CL, Dy-Liacco M, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood. 2006;108:3611–9. https://doi.org/10.1182/blood-2006-04-017467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011;118:5957–64. https://doi.org/10.1182/blood-2011-06-362111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1392–8. https://doi.org/10.1016/j.bbmt.2015.05.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Butler CL, Valenzuela NM, Thomas KA, Reed EF, Not all antibodies are created equal: factors that influence antibody mediated rejection. J Immunol Res. 2017;2017:7903471. https://doi.org/10.1155/2017/7903471.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood. 2007;109:1307–15. https://doi.org/10.1182/blood-2006-05-022772.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47:508–15. https://doi.org/10.1038/bmt.2011.131.

    Article  CAS  PubMed  Google Scholar 

  38. Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol & Oncol. 2015;8:84. https://doi.org/10.1186/s13045-015-0182-9.

    Article  CAS  Google Scholar 

  39. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115:2704–8. https://doi.org/10.1182/blood-2009-09-244525.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116:2839–46. https://doi.org/10.1182/blood-2009-10-249219.

    Article  CAS  PubMed  Google Scholar 

  41. Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE, Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17:1704–8. https://doi.org/10.1016/j.bbmt.2011.04.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691–7. https://doi.org/10.1182/blood-2011-05-355263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica. 2013;98:1154–60. https://doi.org/10.3324/haematol.2012.077685.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K, The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion. 2008;48:791–3. https://doi.org/10.1111/j.1537-2995.2008.01678.x.

    Article  PubMed  Google Scholar 

  45. Picascia A, Grimaldi V, Napoli C, From HLA typing to anti-HLA antibody detection and beyond: the road ahead. Transplant Rev. 2016;30:187–94. https://doi.org/10.1016/j.trre.2016.07.007.

    Article  Google Scholar 

  46. Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE, et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant. 2013;19:647–52. https://doi.org/10.1016/j.bbmt.2013.01.016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Morin-Papunen L, Tiilikainen A, Hartikainen-Sorri AL, Maternal HLA immunization during pregnancy: presence of anti HLA antibodies in half of multigravidous women. Med Biol. 1984;62:323–5.

    CAS  PubMed  Google Scholar 

  48. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B, Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322:1617–21. https://doi.org/10.1056/nejm199006073222301.

    Article  CAS  PubMed  Google Scholar 

  49. Ferrandiz I, Congy-Jolivet N, Del Bello A, Debiol B, Trebern-Launay K, Esposito L, et al. Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies. Am J Transplant. 2016. https://doi.org/10.1111/ajt.13795.

    Article  PubMed  Google Scholar 

  50. Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, et al. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol, Dial, Transplant. 2013;28:2908–18. https://doi.org/10.1093/ndt/gft362.

    Article  CAS  Google Scholar 

  51. Aalten J, Bemelman FJ, van den Berg-Loonen EM, Claas FH, Christiaans MH, de Fijter JW, et al. Pre-kidney-transplant blood transfusions do not improve transplantation outcome: a Dutch national study. Nephrol, Dial, Transplant. 2009;24:2559–66. https://doi.org/10.1093/ndt/gfp233.

    Article  Google Scholar 

  52. Balasubramaniam GS, Morris M, Gupta A, Mesa IR, Thuraisingham R, Ashman N, Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation. 2012;93:418–22. https://doi.org/10.1097/TP.0b013e3182419864.

    Article  PubMed  Google Scholar 

  53. Rees L, Kim JJ, HLA sensitisation: can it be prevented?. Pediatr Nephrol. 2015;30:577–87. https://doi.org/10.1007/s00467-014-2868-6.

    Article  PubMed  Google Scholar 

  54. Patel R, Terasaki PI, Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–9. https://doi.org/10.1056/nejm196904032801401.

    Article  CAS  PubMed  Google Scholar 

  55. Pena JR, Saidman SL, Anti-HLA antibody testing in hematology patients. Am J Hematol. 2015;90:361–4. https://doi.org/10.1002/ajh.23935.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O, Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;2:662–5.

    Article  CAS  Google Scholar 

  57. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19–47. https://doi.org/10.1097/TP.0b013e31827a19cc.

    Article  CAS  PubMed  Google Scholar 

  58. Couzi L, Araujo C, Guidicelli G, Bachelet T, Moreau K, Morel D, et al. Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation. 2011;91:527–35. https://doi.org/10.1097/TP.0b013e31820794bb.

    Article  CAS  PubMed  Google Scholar 

  59. Zachary AA, Ratner LE, Graziani JA, Lucas DP, Delaney NL, Leffell MS, Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol. 2001;62:236–46.

    Article  CAS  Google Scholar 

  60. Pei R, Lee J, Chen T, Rojo S, Terasaki PI, Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol. 1999;60:1293–302.

    Article  CAS  Google Scholar 

  61. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI, Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation. 2003;75:43–9. https://doi.org/10.1097/01.tp.0000040431.80510.98.

    Article  CAS  PubMed  Google Scholar 

  62. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA, Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol. 2009;70:563–8. https://doi.org/10.1016/j.humimm.2009.05.001.

    Article  CAS  PubMed  Google Scholar 

  63. Bartel G, Wahrmann M, Exner M, Regele H, Huttary N, Schillinger M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant.2008;8:41–9. https://doi.org/10.1111/j.1600-6143.2007.01998.x.

    Article  CAS  PubMed  Google Scholar 

  64. Smith JD, Hamour IM, Banner NR, Rose ML, C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant.2007;7:2809–15. https://doi.org/10.1111/j.1600-6143.2007.01991.x.

    Article  CAS  PubMed  Google Scholar 

  65. Chen G, Sequeira F, Tyan DB, Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72:849–58. https://doi.org/10.1016/j.humimm.2011.07.001.

    Article  CAS  PubMed  Google Scholar 

  66. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart lung Transplant. 2011;30:158–63. https://doi.org/10.1016/j.healun.2010.08.020.

    Article  PubMed  Google Scholar 

  67. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB, C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91:342–7. https://doi.org/10.1097/TP.0b013e318203fd26.

    Article  CAS  PubMed  Google Scholar 

  68. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB, Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16:12–7. https://doi.org/10.1111/j.1399-3046.2011.01599.x.

    Article  CAS  PubMed  Google Scholar 

  69. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B, Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood. 1989;74:1477–80.

    CAS  PubMed  Google Scholar 

  70. Damman J, Seelen MA, Moers C, Daha MR, Rahmel A, Leuvenink HG, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011;92:163–9. https://doi.org/10.1097/TP.0b013e318222c9a0.

    Article  CAS  PubMed  Google Scholar 

  71. Muller TF, Kraus M, Neumann C, Lange H, Detection of renal allograft rejection by complement components C5A and TCC in plasma and urine. J Lab Clin Med. 1997;129:62–71.

    Article  CAS  Google Scholar 

  72. Welch TR, Beischel LS, Witte DP, Differential expression of complement C3 and C4 in the human kidney. J Clin Invest. 1993;92:1451–8. https://doi.org/10.1172/jci116722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS, Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation. 2008;86:1319–21. https://doi.org/10.1097/TP.0b013e3181889831.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–26. https://doi.org/10.1056/NEJMoa1302506.

    Article  CAS  PubMed  Google Scholar 

  75. Wang J, Meade JR, Brown NK, Weidner JG, Marino SR, EDTA is superior to DTT treatment for overcoming the prozone effect in HLA antibody testing. Hla. 2017;89:82–9. https://doi.org/10.1111/tan.12950.

    Article  CAS  PubMed  Google Scholar 

  76. Anani WQ, Zeevi A, Lunz JG, EDTA Treatment of serum unmasks complement-mediated prozone inhibition in human leukocyte antigen antibody testing. Am J Clin Pathol. 2016;146:346–52. https://doi.org/10.1093/ajcp/aqw116.

    Article  CAS  PubMed  Google Scholar 

  77. Weinstock C, Schnaidt M, The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet. 2013;40:171–7. https://doi.org/10.1111/j.1744-313X.2012.01147.x.

    Article  CAS  PubMed  Google Scholar 

  78. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D, HLA antibody specification using single-antigen beads--a technical solution for the prozone effect. Transplantation. 2011;92:510–5. https://doi.org/10.1097/TP.0b013e31822872dd.

    Article  CAS  PubMed  Google Scholar 

  79. Ratkovec RM, Hammond EH, O’Connell JB, Bristow MR, DeWitt CW, Richenbacher WE, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch--preliminary results with plasmapheresis. Transplantation. 1992;54:651–5.

    Article  CAS  Google Scholar 

  80. Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, Silver MA, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart lung Transplant. 1999;18:701–6.

    Article  CAS  Google Scholar 

  81. Grauhan O, Knosalla C, Ewert R, Hummel M, Loebe M, Weng YG, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart lung Transplant. 2001;20:316–21.

    Article  CAS  Google Scholar 

  82. Baran DA, Lubitz S, Alvi S, Fallon JT, Kaplan S, Galin I, et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc. 2004;36:3164–6. https://doi.org/10.1016/j.transproceed.2004.10.087.

    Article  CAS  PubMed  Google Scholar 

  83. Everly JJ, Walsh RC, Alloway RR, Woodle ES, Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant. 2009;14:662–6. https://doi.org/10.1097/MOT.0b013e328330f304.

    Article  PubMed  Google Scholar 

  84. Maruta A, Fukawa H, Kanamori H, Harano H, Noguchi T, Kodama F, et al. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Bone Marrow Transplant. 1991;7:397–400.

    CAS  PubMed  Google Scholar 

  85. Braun N, Faul C, Wernet D, Schnaidt M, Stuhler G, Kanz L, et al. Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA-sensitized patient treated with immunoadsorption onto protein A. Transplantation. 2000;69:1742–4.

    Article  CAS  Google Scholar 

  86. Pollack MS, Ririe D, Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens. Hum Immunol. 2004;65:245–7. https://doi.org/10.1016/j.humimm.2003.12.010.

    Article  CAS  PubMed  Google Scholar 

  87. Leffell MS, Jones RJ, Gladstone DE, Donor HLA-specific Abs: to BMT or not to BMT?. Bone Marrow Transplant. 2015;50:751–8. https://doi.org/10.1038/bmt.2014.331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Yamashita T, Ikegame K, Kojima H, Tanaka H, Kaida K, Inoue T, et al. Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:794–6. https://doi.org/10.1038/bmt.2017.10.

    Article  CAS  PubMed  Google Scholar 

  89. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365:318–26. https://doi.org/10.1056/NEJMoa1012376.

    Article  CAS  PubMed  Google Scholar 

  90. Kongtim P, Cao K, Ciurea SO, Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol. 2016;2016:4025073. https://doi.org/10.1155/2016/4025073.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Ottinger HD, Rebmann V, Pfeiffer KA, Beelen DW, Kremens B, Runde V, et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation. 2002;73:1280–5.

    Article  Google Scholar 

  92. Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S, et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant. 2005;36:555–6. https://doi.org/10.1038/sj.bmt.1705070.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Stefan O. Ciurea & Kai Cao

  2. Stanford University, Stanford, CA, USA

    Marcelo Fernandez-Vina

  3. Thammasat University, Bangkok, Thailand

    Piyanuch Kongtim

  4. Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA

    Monzr Al Malki

  5. Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

    Ephraim Fuchs & Leo Luznik

  6. Institute of Hematology, Peking University People’s Hospital, Beijing, China

    Xiao-Jun Huang

  7. Hematology and BMT Unit, San Raffaele Scientific Institute, Milan, Italy

    Fabio Ciceri

  8. Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy

    Franco Locatelli

  9. Hematology and BMT Unit, University of Parma, Parma, Italy

    Franco Aversa

  10. Hematology Department, Humanitas Clinical and Research Center, Milan, Italy

    Luca Castagna

  11. Instituto di Ematologia, Fondazione Policlinico Universitario Gemelli, Universita’ Cattolica del Sacro Cuore, Roma, Italy

    Andrea Bacigalupo

  12. University of Perugia, Perugia, Italy

    Massimo Martelli

  13. Departement D’Hematologie, Programme de Transplantation et de Therapie Cellulaire, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France

    Didier Blaise

  14. Department of Hematology and Oncology, Children’s University Hospital, Tubingen, Germany

    Rupert Handgretinger

  15. Blood and Marrow Transplantation Program, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada

    Denis-Claude Roy

  16. Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Paul O’Donnell

  17. BMT Program at Northside Hospital, Atlanta, GA, USA

    Asad Bashey

  18. Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus

  19. University of Virginia Health System, Charlottesville, VA, USA

    Karen Ballen

  20. Vanderbilt University Medical Center, Nashville, TN, USA

    Bipin N. Savani

  21. Hopital Saint-Antoine, Paris, France

    Mohamad Mohty

  22. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel

    Arnon Nagler

  23. Acute Leukemia Working Party of the EBMT, Hopital Saint-Antoine, Paris, France

    Arnon Nagler

Authors
  1. Stefan O. Ciurea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcelo Fernandez-Vina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Piyanuch Kongtim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Monzr Al Malki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ephraim Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Leo Luznik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao-Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fabio Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Franco Locatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Franco Aversa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Luca Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Andrea Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Massimo Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Rupert Handgretinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Denis-Claude Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Paul O’Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Asad Bashey
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Hillard M. Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Karen Ballen
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Bipin N. Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan O. Ciurea.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ciurea, S.O., Cao, K., Fernandez-Vina, M. et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant 53, 521–534 (2018). https://doi.org/10.1038/s41409-017-0062-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-017-0062-8

This article is cited by

Search

Advanced search

Quick links